Aisah A. Aubdool
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aisah A. Aubdool has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Susan Diana Brain
Section of Vascular Biology & Inflammation, School of Cardiovascular and Metabolic Medicine & Sciences (South Bank), BHF Centre of Research Excellence, King’s College London, United Kingdom (B.D.S.).
4 shared publications - Elizabeth Soares Fernandes
Department of Animal and Veterinary Sciences-ANIVET Ruminant Nutrition (RUN), Aarhus University, 8830 Tjele, Denmark
2 shared publications Jennifer V. Bodkin
Cardiovascular Division British Heart Foundation King's College London Cardiovascular Centre of Excellence London UK
2 shared publications- Stuart Bevan
Wolfson Sensory Pain and Regeneration Centre (SpaRC), Institute of Psychiatry, Psychology & Neuroscience, King's College London, London SE1 1UL, United Kingdom
2 shared publications - Chi Teng Vong
The State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau; Macau Centre for Research and Development in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau
1 shared publication Clive Gentry
Wolfson Centre for Age Related Disease King's College London London UK
1 shared publication
Latest Publications
- Open Access
- 27 December 2012
- Published by Wiley in The FASEB Journal
- Vol. 27 (4) , 1664-1673
Superoxide generation and leukocyte accumulation: key elements in the mediation of leukotriene B 4 ‐induced itch by transient receptor potential ankyrin 1 and transient receptor potential vanilloid 1
The underlying mechanisms of itch are poorly understood. We have investigated a model involving the chemoattractant leukotriene B 4 (LTB 4 ) that is up‐regulated in common skin diseases. Intradermal injection of LTB 4 (0.1 nmol/site) into female CD1 mice induced significant scratching movements (used as an itch index) compared with vehicle‐injected (0.1% bovine serum albumin‐saline) mice. Intraperitoneal transient receptor potential (TRP) channel antagonist treatment significantly inhibited itch as follows: TRP vanilloid 1 (TRPV1) antagonist SB366791 (0.5 mg/kg, by 97%) and the TRP ankyrin 1 (TRPA1) antagonists TCS 5861528 (10 mg/kg; 82%) and HC‐030031 (100 mg/kg; 76%). Leukotriene B 4 receptor 2 antagonism by LY255283 (5 mg/kg i.p.; 62%) reduced itch. Neither TRPV1‐knockout (TRPV1‐KO) nor TRPA1‐knockout (TRPA1‐KO mice exhibited LTB 4 ‐induced itch compared with their wild‐type counterparts. The reactive oxygen species scavengers N ‐acetylcysteine (NAC; 204 mg/kg i.p.; 86%) or superoxide dismutase (SOD; 10 mg/kg i.p.; 83%) also inhibited itch. LTB 4 ‐induced superoxide release was attenuated by TCS 5861528 (56%) and HC‐030031 (66%), NAC (58%), SOD (50%), and LY255283 (59%) but not by the leukotriene B 4 receptor 1 antagonist U‐75302 (9 nmol/site) or SB366791. Itch, superoxide, and myeloperoxidase generation were inhibited by the leukocyte migration inhibitor fucoidan (10 mg/kg i.v.) by 80, 61, and 34%, respectively. Myeloperoxidase activity was also reduced by SB366791 (35%) and SOD (28%). TRPV1‐KO mice showed impaired myeloperoxidase release, whereas TRPA1‐KO mice exhibited diminished production of superoxide. This result provides novel evidence that TRPA1 and TRPV1 contribute to itch via distinct mechanisms.—Fernandes, E. S., Vong, C. T., Quek, S., Cheong, J., Awal, S., Gentry, C., Aubdool, A. A., Liang, L., Bodkin, J.V., Bevan, S., Heads, R., Brain, S.D. Superoxide generation and leukocyte accumulation: key elements in the mediation of leukotriene B 4 ‐induced itch by transient receptor potential ankyrin 1 and transient receptor potential vanilloid 1. FASEB J. 27, 1664–1673 (2013). www.fasebj.org
- 27 December 2012
- Published by Wiley in The FASEB Journal
- Vol. 27 (4) , 1664-1673
Open AccessSuperoxide generation and leukocyte accumulation: key elements in the mediation of leukotriene B 4 ‐induced itch by transient receptor potential ankyrin 1 and transient receptor potential vanilloid 1
The underlying mechanisms of itch are poorly understood. We have investigated a model involving the chemoattractant leukotriene B 4 (LTB 4 ) that is up‐regulated in common skin diseases. Intradermal injection of LTB 4 (0.1 nmol/site) into female CD1 mice induced significant scratching movements (used as an itch index) compared with vehicle‐injected (0.1% bovine serum albumin‐saline) mice. Intraperitoneal transient receptor potential (TRP) channel antagonist treatment significantly inhibited itch as follows: TRP vanilloid 1 (TRPV1) antagonist SB366791 (0.5 mg/kg, by 97%) and the TRP ankyrin 1 (TRPA1) antagonists TCS 5861528 (10 mg/kg; 82%) and HC‐030031 (100 mg/kg; 76%). Leukotriene B 4 receptor 2 antagonism by LY255283 (5 mg/kg i.p.; 62%) reduced itch. Neither TRPV1‐knockout (TRPV1‐KO) nor TRPA1‐knockout (TRPA1‐KO mice exhibited LTB 4 ‐induced itch compared with their wild‐type counterparts. The reactive oxygen species scavengers N ‐acetylcysteine (NAC; 204 mg/kg i.p.; 86%) or superoxide dismutase (SOD; 10 mg/kg i.p.; 83%) also inhibited itch. LTB 4 ‐induced superoxide release was attenuated by TCS 5861528 (56%) and HC‐030031 (66%), NAC (58%), SOD (50%), and LY255283 (59%) but not by the leukotriene B 4 receptor 1 antagonist U‐75302 (9 nmol/site) or SB366791. Itch, superoxide, and myeloperoxidase generation were inhibited by the leukocyte migration inhibitor fucoidan (10 mg/kg i.v.) by 80, 61, and 34%, respectively. Myeloperoxidase activity was also reduced by SB366791 (35%) and SOD (28%). TRPV1‐KO mice showed impaired myeloperoxidase release, whereas TRPA1‐KO mice exhibited diminished production of superoxide. This result provides novel evidence that TRPA1 and TRPV1 contribute to itch via distinct mechanisms.—Fernandes, E. S., Vong, C. T., Quek, S., Cheong, J., Awal, S., Gentry, C., Aubdool, A. A., Liang, L., Bodkin, J.V., Bevan, S., Heads, R., Brain, S.D. Superoxide generation and leukocyte accumulation: key elements in the mediation of leukotriene B 4 ‐induced itch by transient receptor potential ankyrin 1 and transient receptor potential vanilloid 1. FASEB J. 27, 1664–1673 (2013). www.fasebj.org
- 1 December 2011
- Published by Elsevier in Journal of Investigative Dermatology Symposium Proceedings
- Vol. 15 (1) , 33-39
Neurovascular Aspects of Skin Neurogenic Inflammation
- 1 December 2011
- Published by Elsevier in Journal of Investigative Dermatology Symposium Proceedings
- Vol. 15 (1) , 33-39
Neurovascular Aspects of Skin Neurogenic Inflammation
- 1 August 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (16) , 4857-4859
Design and pharmacological evaluation of PF-4840154, a non-electrophilic reference agonist of the TrpA1 channel
- 1 August 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (16) , 4857-4859
Design and pharmacological evaluation of PF-4840154, a non-electrophilic reference agonist of the TrpA1 channel
- 1 April 2011
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 337 (1) , 117-124
4-Oxo-2-nonenal (4-ONE): Evidence of Transient Receptor Potential Ankyrin 1-Dependent and -Independent Nociceptive and Vasoactive Responses In Vivo
This study explores the in vivo effects of the proposed transient receptor potential ankyrin 1 (TRPA1) agonist 4-oxo-2-nonenal (4-ONE). Pharmacological inhibitors and genetically modified mice were used to investigate the ability of 4-ONE to act via TRPA1 receptors and possible mechanisms involving transient receptor potential vanilloid 1 (TRPV1). We hypothesized that 4-ONE activates sensory nerves, via TRPA1 or possibly TRPV1, and thus triggers mechanical hyperalgesia, edema formation, and vasodilatation in mice. An automated dynamic plantar aesthesiometer was used to determine hind paw withdrawal thresholds, and a laser Doppler flowmeter was used to measure skin blood flow. Edema formation was determined by measuring paw weights and thickness. 4-ONE (10 nmol) triggers unilateral mechanical hyperalgesia, edema formation, and vasodilatation in mice and is shown here to exhibit TRPA1-dependent and -independent effects. Neurogenic vasodilatation and mechanical hyperalgesia at 0.5 h postinjection were significantly greater in TRPA1 wild-type (WT) mice compared with TRPA1 knockout (KO) mice. Edema formation throughout the time course as well as mechanical hyperalgesia from 1 to 4 h postinjection were similar in WT and TRPA1 KO mice. Studies involving TRPV1 KO mice revealed no evidence of TRPV1 involvement or interactions between TRPA1 and TRPV1 in mediating the in vivo effects of 4-ONE. Previously, 4-ONE was shown to be a potent TRPA1 agonist in vitro. We demonstrate its ability to mediate vasodilatation and certain nociceptive effects in vivo. These data indicate the potential of TRPA1 as an oxidant sensor for vasodilator responses in vivo. However, 4-ONE also triggers TRPA1-independent effects that relate to edema formation and pain.
- 1 April 2011
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 337 (1) , 117-124
4-Oxo-2-nonenal (4-ONE): Evidence of Transient Receptor Potential Ankyrin 1-Dependent and -Independent Nociceptive and Vasoactive Responses In Vivo
This study explores the in vivo effects of the proposed transient receptor potential ankyrin 1 (TRPA1) agonist 4-oxo-2-nonenal (4-ONE). Pharmacological inhibitors and genetically modified mice were used to investigate the ability of 4-ONE to act via TRPA1 receptors and possible mechanisms involving transient receptor potential vanilloid 1 (TRPV1). We hypothesized that 4-ONE activates sensory nerves, via TRPA1 or possibly TRPV1, and thus triggers mechanical hyperalgesia, edema formation, and vasodilatation in mice. An automated dynamic plantar aesthesiometer was used to determine hind paw withdrawal thresholds, and a laser Doppler flowmeter was used to measure skin blood flow. Edema formation was determined by measuring paw weights and thickness. 4-ONE (10 nmol) triggers unilateral mechanical hyperalgesia, edema formation, and vasodilatation in mice and is shown here to exhibit TRPA1-dependent and -independent effects. Neurogenic vasodilatation and mechanical hyperalgesia at 0.5 h postinjection were significantly greater in TRPA1 wild-type (WT) mice compared with TRPA1 knockout (KO) mice. Edema formation throughout the time course as well as mechanical hyperalgesia from 1 to 4 h postinjection were similar in WT and TRPA1 KO mice. Studies involving TRPV1 KO mice revealed no evidence of TRPV1 involvement or interactions between TRPA1 and TRPV1 in mediating the in vivo effects of 4-ONE. Previously, 4-ONE was shown to be a potent TRPA1 agonist in vitro. We demonstrate its ability to mediate vasodilatation and certain nociceptive effects in vivo. These data indicate the potential of TRPA1 as an oxidant sensor for vasodilator responses in vivo. However, 4-ONE also triggers TRPA1-independent effects that relate to edema formation and pain.